for people ages 2-11 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:
Philip Rosenthal



This placebo-controlled study evaluates the efficacy, safety and tolerability of tenofovir disoproxil fumarate (TDF) in participants 2 to < 12 years old with chronic Hepatitis B infection. While studies have shown significant virologic response in adults and adolescents, the effect in children is not well established. This study will provide valuable data that can help establish the efficacy and safety profiles of TDF in children. The study will consist of 48 weeks of blinded randomized treatment, after which participants will switch to open-label TDF treatment for an additional 144 weeks.

Official Title

A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients With Chronic Hepatitis B Infection


Chronic Hepatitis B Infection Hepatitis Hepatitis B HBV Infection Communicable Diseases Hepatitis A Hepatitis, Chronic Hepatitis B, Chronic Tenofovir Tenofovir DF


For people ages 2-11

Key Inclusion Criteria:

  • Male or Female, 2 to < 12 years of age
  • Weight ≥ 10kg
  • Chronic HBV infection ≥ 6 months
  • HBeAg-positive or HBeAg-negative
  • HBV Viral Load ≥ 100,000 copies/mL
  • Alanin aminotransferase (ALT) ≥ 1.5 x the upper limit of the normal range (ULN) at screening
  • Creatinine Clearance ≥ 80 mL/min
  • Absolute neutrophil count (ANC) ≥ 1,500/mm3, hemoglobin ≥ 10g/dL

  • Negative pregnancy test at screening
  • No prior tenofovir DF therapy (subjects may have received prior interferon‑alfa and/or other oral anti‑HBV nucleoside/nucleotide therapy; subjects must have discontinued interferon-alfa therapy ≥ 6 months prior to screening; subjects experienced on other anti-HBV nucleoside/nucleotide therapy must have discontinued therapy ≥ 16 weeks prior to screening to avoid flare if randomized to the placebo arm)

Key Exclusion Criteria:

  • Pregnant or lactating
  • Decompensated liver disease
  • Received interferon therapy within 6 months of Screening
  • Received anti-HBV nucleoside/nucleotide therapy within 16 weeks of Screening
  • Alpha-fetoprotein levels > 50 ng/mL
  • Evidence of hepatocellular carcinoma (HCC)
  • Co-infection with HIV, acute hepatitis A virus (HAV), hepatitis C virus (HCV), or hepatitis D virus (HDV)
  • Chronic liver disease not due to HBV
  • History of significant renal, cardiovascular, pulmonary, neurological or bone disease
  • Long term non-steroidal, anti-inflammatory drug therapy

Note: Other protocol defined Inclusion/Exclusion criteria may apply


  • University of California, San Francisco
    San Francisco California 94143 United States
  • Phoenix Children's Hospital
    Phoenix Arizona 85016 United States
  • Children's Hospital Colorado
    Aurora Colorado 80045 United States
  • Texas Children's Hospital
    Houston Texas 77030 United States


in progress, not accepting new patients
Start Date
Completion Date
Gilead Sciences
Phase 3
Lead Scientist
Philip Rosenthal
Study Type
Last Updated
January 24, 2018